Reportlinker.com announces that a new market research report is available in its catalogue: Monoclonal Antibody Based Products - Global Trends
http://www.reportlinker.com/p0164349/Monoclonal-Antibody-Based-Products---Global-Trends.html
Monoclonal antibodies represent one of the successes of the biotechnology industry along with a broad range of therapeutics and diagnostics. Monoclonal Antibody (MAb)-based products market is one of the fastest growing categories of the biopharmaceuticals industry. These products are of high significance for pharmaceutical industry, both in research as well as drug development activities. MAbs function as production repositories for developing drugs, and are used in the manufacture of highly specialized diagnostic products. Rapid technological advancements that enable antibodies to specifically target disease-causing cells are expected to boost prospects in the global therapeutic and diagnostic monoclonal antibodies market.
These and other market data and trends are presented in "Monoclonal Antibody-Based Products: Global Trends" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
MONOCLONAL ANTIBODY BASED PRODUCTS BMR-1149
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4
MAb Market - Set for Significant Growth 4
Therapeutic mAb Market - Principal Driving Force 5
Development of New MAbs on a Fast Track 6
Genomics Research Leads Way to New Monoclonal Antibodies 6
Bright Outlook for Mabs 7
Current and Future Analysis 7
Product Segment Perspective 7
Competitive Scenario 7
Intensifying Consolidation Activity 8
Drug Developers Trying to Break the Shackles 11
Rituximab Vs. Epratuzumab 11
A Revolution Not too Far 11
Milestones in Development of MAbs 11
Focus on Unmet Medical Needs in the Emerging Markets 12
3. TRENDS AND ISSUES 12
Shift Towards Humanized and Fully Human Antibodies 12
Ageing Baby Boomers Spur MAbs Growth 12
Non-Existent Generic Competition Favors MAb Market 13
Partnerships and Collaborations Spark Increase in Profit Margins 13
Pharma Majors & CMOs Augment Investment in Mab Production 13
Rising Number of MAbs Under Clinical Trials 14
Select Clinical Trials for Monoclonal Antibodies 14
Major Monoclonal Antibodies in Phase III Trials Across the World 15
High Costs Impede MAbs Penetration 16
Opportunities in Technology Development 16
Advancements & Challenges in Antibody Production Processes 17
Increasing Demand for Protein A in Mab Manufacturing 17
FCA- A Major Cause for Discomfort in Mice 17
Innovations to Drive Growth in Anti-Ovarian Cancer Drugs Market 18
Rising Incidence of NHL to Drive Monoclonal Antibody Drug Market 18
4. PRODUCT FACTS 19
A.Therapeutics 19
Cancer 19
Other Therapeutic Mabs 20
B.Diagnostics 20
Types of Monoclonal Antibodies 20
5. CORPORATE DEVELOPMENTS 21
Callisto Merger Corporation Merges with Celldex Therapeutics 21
SDI to Develop mAbs for SAIC-F and NCI 21
HGS Reacquires Rights for TRAIL Receptor Antibodies 22
Amgen Enters into Licensing Agreement with Kyowa Hakko 22
Dyax and Sanofi-Aventis Sign Agreements 22
HGS Enters into Antibody Collaboration Agreement with Xencor 23
Amgen Introduces Vectibix 23
UCB Receives FDA Approval for Cimzia® 23
Genentech Acquires Tanox 23
Biotest Acquires Assets of Nabi Biologics 24
CMC Acquires ICOS Biologics Operation 24
Roche Takes Over THP 24